Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Nimes – page 15

342 clinical trials in Nimes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Nimes at a glance
342
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

342 trials in Nimes

Open in trial search

Atrial fibrillation

Not yet recruiting

Preventing atrial fibrillation after cardiac surgery using colchicine, amiodarone and posterior pericardiotomy in adult patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Not yet recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Small cell lung cancer limited stage

Not yet recruiting

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Pharmacosmos A/S

Myocardial infarction

Not yet recruiting

Ticagrelor monotherapy vs ticagrelor plus acetylsalicylic acid in patients with myocardial infarction treated medically

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Montreal Heart Institute

Breast cancer

Not yet recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Neuromyelitis optica spectrum disorder+1

Not yet recruiting

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Parkinson's disease

Not yet recruiting

Effect of botulinum toxin type A - haemagglutinin complex on refractory upper‑limb resting tremor in Parkinson disease patients (drug‑combination study)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nitrous Oxide
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Breast cancer

Not yet recruiting

Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin Sodium
  • Sponsor:University Hospital Of Clermont-Ferrand

Systemic lupus erythematosus

Not yet recruiting

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Focal segmental glomerulosclerosis

Not yet recruiting

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Study of Surovatamig and Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19 in Adults with Antibody-Mediated Kidney Disease

Not yet recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Nimes

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Innovative trials focusing on cardiovascular conditions and metabolic disorders, examining new therapeutic approaches for heart and diabetes-related complications.

  • Atrial Fibrillation & Acute Coronary Syndrome Management
  • Type 2 Diabetes Cardiovascular Prevention
  • Chronic Kidney Disease Treatment

Studies evaluating novel drug combinations and monitoring strategies to improve patient outcomes.

02 Oncology Studies

Advanced research in cancer treatment, with particular focus on innovative therapies for various types of cancer.

  • Multiple Myeloma Therapy
  • Prostate Cancer Diagnostics
  • Triple Negative Breast Cancer Treatment

Trials exploring new treatment combinations and diagnostic approaches for better patient care.

03 Neurological Disorders

Comprehensive research into multiple sclerosis and other neurological conditions, testing innovative treatment approaches.

  • Progressive Multiple Sclerosis Therapies
  • Essential Tremor Treatment
  • Diabetic Peripheral Neuropathy

Focus on developing targeted therapies for various neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.